The role of Foxp3+ T cells in long‐term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice
Abstract
Background: Mucosal tolerance induction is suggested as treatment strategy for allergic diseases. Using a murine model of birch pollen (BP) allergy we investigated the long‐term efficacy and the underlying mechanisms of mucosal tolerance induction with two structurally different molecules in a prophylactic and in a therapeutic set‐up.Methods: The three‐dimensional major BP allergen Bet v 1 or a nonconformational hypoallergenic fragment thereof was intranasally applied before (prophylaxis) or after sensitization (therapy).Results: In the prophylactic application both the Bet v 1 allergen and the fragment prevented allergic sensitization, and this effect lasted for 1 year. In the therapeutic approach established allergic immune responses were also suppressed after treatment with either of the molecules. However, a long‐lasting curative effect (6 months) was only achieved with the Bet v 1 allergen but not with the Bet v 1 fragment.Real‐time reverse transcriptase polymerase chain reaction (RT‐PCR) analysis of splenocytes revealed that tolerance induction with the Bet v 1 allergen was associated with enhanced expression of transforming growth factor (TGF)‐β, interleukin (IL)‐10, and Foxp3 mRNA in CD4+ T cells, whereas treatment with the fragment led to the induction of either Foxp3 (prophylaxis) or IL‐10 (therapy) alone.Conclusion: From these data we concluded (i) that the mechanisms underlying peripheral tolerance are linked to the conformation of the antigen, (ii) that mucosal tolerance is mediated by separate regulatory cell subsets, and (iii) that the long‐term efficacy of immunosuppression is associated with the presence of Foxp3+ T cells.Keywords
This publication has 36 references indexed in Scilit:
- Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in miceJournal of Allergy and Clinical Immunology, 2005
- Mechanisms of tolerance induced by TGFβ‐treated APC: CD4 regulatory T cells prevent the induction of the immune response possibly through a mechanism involving TGFβEuropean Journal of Immunology, 2004
- Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 Journal of Experimental Medicine, 2003
- Allergen‐specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergyImmunology, 2003
- Foxp3 programs the development and function of CD4+CD25+ regulatory T cellsNature Immunology, 2003
- Control of Regulatory T Cell Development by the Transcription Factor Foxp3Science, 2003
- In Vitro Generation of Interleukin 10–producing Regulatory CD4+ T Cells Is Induced by Immunosuppressive Drugs and Inhibited by T Helper Type 1 (Th1)– and Th2-inducing CytokinesJournal of Experimental Medicine, 2002
- Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild‐type by skin prick and intradermal testing: results obtained in a French populationClinical & Experimental Allergy, 2000
- Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy.Journal of Clinical Investigation, 1997
- Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy.Journal of Experimental Medicine, 1996